Nicholas Stanzione MD on Muck Rack

Nicholas Stanzione MD

As seen in: Associated Press: Press Releases, Morningstar, WOOD-TV (Grand Rapids, MI), KTVX-TV (Salt Lake City, UT), KRQE-TV (Albuquerque, NM), WIVB-TV (Buffalo, NY), finanzen.net, BioSpace, KSNT-TV (Topeka, KS), WTRF-TV (Wheeling, WV) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nicholas

Contact Nicholas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PreciseDxⓇ Presents New Data for PreciseBreastⓇ, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium

|
By Michael Donovan, Talar Telvizian, Nicholas Stanzione MD
| Associated Press: Press Releases
NEW YORK, Dec. 4, 2025 /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further validate the test’s ability to assess risk of recurrence in early-stage breast cancer. Ongoing studies aim to demonstrate PreciseBreast’s ability to predict treatment benefit.
Open in Who Shared View Duplicates (24) Issue with article?

PreciseDxⓇ Presents New Data for PreciseBreastⓇ, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium

|
By Michael Donovan, Nicholas Stanzione MD, Talar Telvizian, Precise Dx
| WTRF-TV (Wheeling, WV) Verified
PreciseDxⓇ Presents New Data for PreciseBreastⓇ, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium News provided by Dec 04, 2025, 7:00 AM ET , /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further validate the test's ability to assess risk of recurrence in early-stage breast cancer.
Open in Who Shared Issue with article?
See all 15 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified